Determining the role of NLRP3 on the placement and protective potential of CD73+ BRMs post influenza infection
确定 NLRP3 对流感感染后 CD73 BRM 的放置和保护潜力的作用
基本信息
- 批准号:10393080
- 负责人:
- 金额:$ 20.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-01 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:AdenosineAffinityAntibodiesAntibody FormationAntibody ResponseAntigensAreaB cell differentiationB-LymphocytesBiological AssayCell CommunicationCell Differentiation processCellsCenters for Disease Control and Prevention (U.S.)Cessation of lifeComplexConsequentialismDataDevelopmentDiseaseEmigrantFutureGenesGrantHemagglutininHistologyHomeImageImmuneImmunityImmunoglobulin-Secreting CellsIn SituIn VitroIndividualInfectionInflammasomeInfluenzaInterleukin-6InterleukinsInvadedInvestigationKnockout MiceLightLocationLungLymphoid TissueMaintenanceMemoryMemory B-LymphocyteMolecular TargetMorbidity - disease rateMusMutationOutcomePhenotypePopulationProductionPropertyPublic HealthReactionReporterReportingResearch PersonnelResistanceResolutionRoleSentinelSignal TransductionStructure of germinal center of lymph nodeT cell responseT-LymphocyteTNFRSF5 geneTarget PopulationsTestingTissuesVaccinationVaccine DesignVaccinesViralVirusbasecross reactivitycytokineeffector T cellfunctional outcomesin vitro Assayinfluenza infectionlymph nodeslymphoid organlymphoid structuresmacrophagemortalityneutralizing antibodynovelpathogenplasma cell differentiationpopulation basedpulmonary functionreceptorresponsetranscriptometranscriptome sequencingvaccine accessvaccine immunotherapy
项目摘要
Project Summary
Little is known about antigen (Ag) specific memory B (BMEM) cells, in the context of a public health relevant
pathogen. Our studies clearly resolve the subsets of non-circulating, influenza specific, resident memory B
cells (BRM) in the lung. BRM establishment relied on early CD40 signaling and maintained a CD73
(ectoenzyme)+ and CD73- population, whereas the lymph node (LN) showed a decline in the CD73-
population. This raised the question of the inherent differences in formation and function of CD73+ and CD73-
BRMs. CD73 is a marker of germinal center (GC) emigrants in the LN and memory cells in the LN reside in
niches close to macrophages that capture and transfer antigen and T cells which can provide help; therefore,
we hypothesized that the CD73+BRMs will home to areas of organized lymphoid structures in the lung and be
dependent on T cell help. Our RNASeq data shows NLRP3 (NOD-like receptor protein 3), an innate danger
sensing complex, to be the most upregulated gene in CD73+BRMs. To our knowledge NLRP3 activity is not
associated with B cell differentiation, which makes this finding novel and may inaugurate studies into innate
like functions in B cells during adaptive responses. NLRP3 activity produces interleukin B (IL-1B) and IL-1B is
a well-known up regulator of interleukin 6 (IL-6), which promotes GCs and plasma cell differentiation. As our
CD73+BRMs may have higher NLRP3 expression, we hypothesize that NLRP3 will be active during recall and
produce GCs and ASCs, while the CD73-BRMs may be sentinels in the lung which spontaneously convert to
ASCs, in response to the returning virus.
To test these hypotheses, we ask the following: 1) Are CD73+ and CD73- BRM cells dependent on GCs? If
so, GC-specific blockade should reduce CD73+ BRMs in the lung and produce low affinity BCRs. 2) Do CD73+
BRMs preferentially reside in iBALT? If so, using histology, we should observe them congregating in the
iBALT while the CD73-BRMs are scattered in the parenchyma. 3) Do CD73+ and CD73- BRM cells respond
differently in functional assays? We will answer this question by performing in vitro assays for BRM
differentiation to ASCs, using cytokine cocktails and sorted T cells. 4) Does the NLRP3 complex become
activated in BRMs upon viral challenge? If so, using NLRP3 inflammasome reporter mice, we expect that
CD73+ BRM cells, but not CD73- BRM cells to increase NLRP3 activity. 5) Does NLRP3 regulate the
formation or function of BRMs? If so, B cell specific NLRP3 deficiency should alter the proportions of
CD73+ and CD73-BRMs and their protective function with observable differences in morbidity and mortality.
The findings from this study despite the outcome will be extremely important to allow for the resolution of a
target population and potential molecular targets for an effective vaccine design.
项目摘要
在与公共卫生相关的背景下,对抗原(Ag)特异性记忆B(BMEM)细胞知之甚少
病原体。我们的研究清楚地解析了非循环、流感特异性、居民记忆B的子集
肺中的细胞(BRM)。BRM的建立依赖于早期的CD40信号,并维持CD73
(胞外酶)+和CD73-群体,而淋巴结(LN)CD73-
人口。这就提出了CD73+和CD73在形成和功能上的内在差异的问题-
BRMS。CD73是LN中生发中心(GC)迁移的标志,LN中的记忆细胞驻留在
靠近巨噬细胞捕获和转移抗原的壁龛,以及可以提供帮助的T细胞;因此,
我们假设CD73+BRM将是肺中有组织的淋巴结构区域的归宿,并
依赖T细胞的帮助。我们的RNAseq数据显示NLRP3(节点样受体蛋白3)是一种先天危险
感觉复合体,可能是CD73+BRM中表达最高的基因。据我们所知,NLRP3活动不是
与B细胞分化有关,这使得这一发现具有新颖性,并可能开启对先天
B细胞在适应性反应中的类似功能。NLRP3活性产生白介素B(IL-1B),而IL-1B
一种众所周知的白介素6(IL-6)的上调调节剂,可促进GC和浆细胞分化。作为我们的
CD73+BRM可能有较高的NLRP3表达,我们假设NLRP3在回忆和
产生GC和ASCs,而CD73-BRM可能是肺中的哨兵,自发地转化为
ASCs,作为对返回的病毒的响应。
为了验证这些假设,我们问了以下问题:1)CD73+和CD73-BRM细胞依赖于GC吗?如果
因此,GC特异性阻断应该会减少肺中CD73+BRM,并产生低亲和力的BCR。2)做CD73+
BRMS优先驻留在iBALT?如果是这样的话,利用组织学,我们应该观察到它们聚集在
CD73-BRM散在分布于实质内。3)CD73+和CD73-BRM细胞是否有反应
在功能分析上有什么不同?我们将通过对BRM进行体外检测来回答这个问题
使用细胞因子鸡尾酒和分选的T细胞向ASCs分化。4)NLRP3复合体是否会变成
在病毒挑战时在BRMS中被激活?如果是这样的话,使用NLRP3炎症报告小鼠,我们预计
CD73+BRM细胞,而不是CD73-BRM细胞增加NLRP3活性。5)NLRP3是否调节
BRM的形成或功能?如果是这样的话,B细胞特异性NLRP3缺陷应该会改变
CD73+和CD73-BRM及其保护功能在发病率和死亡率方面有明显差异。
不管结果如何,这项研究的结果将对解决
有效疫苗设计的目标人群和潜在的分子目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
S Rameeza Allie其他文献
S Rameeza Allie的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('S Rameeza Allie', 18)}}的其他基金
Establishment and metabolic control of influenza-specific lung-resident memory B cells
流感特异性肺驻留记忆 B 细胞的建立和代谢控制
- 批准号:
8982505 - 财政年份:2015
- 资助金额:
$ 20.27万 - 项目类别:
Establishment and metabolic control of influenza-specific lung-resident memory B cells
流感特异性肺驻留记忆 B 细胞的建立和代谢控制
- 批准号:
9120660 - 财政年份:2015
- 资助金额:
$ 20.27万 - 项目类别:
相似海外基金
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
- 批准号:
10549640 - 财政年份:2023
- 资助金额:
$ 20.27万 - 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
- 批准号:
2750554 - 财政年份:2021
- 资助金额:
$ 20.27万 - 项目类别:
Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
- 批准号:
61319 - 财政年份:2020
- 资助金额:
$ 20.27万 - 项目类别:
Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10013588 - 财政年份:2020
- 资助金额:
$ 20.27万 - 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
- 批准号:
20K07009 - 财政年份:2020
- 资助金额:
$ 20.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
- 批准号:
10603473 - 财政年份:2020
- 资助金额:
$ 20.27万 - 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
- 批准号:
2342674 - 财政年份:2020
- 资助金额:
$ 20.27万 - 项目类别:
Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
- 批准号:
10117194 - 财政年份:2020
- 资助金额:
$ 20.27万 - 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10115604 - 财政年份:2020
- 资助金额:
$ 20.27万 - 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
- 批准号:
10294224 - 财政年份:2018
- 资助金额:
$ 20.27万 - 项目类别: